Wnt/β-catenin signaling pathway activation reverses gemcitabine resistance by attenuating Beclin1-mediated autophagy in the MG63 human osteosarcoma cell line

Tao,Hao; Chen,Feng; Liu,Haifei; Hu,Yanling; Wang,Yingzhen; Li,Haiyan

doi:10.3892/mmr.2017.6828

Wnt/β-catenin signaling pathway activation reverses gemcitabine resistance by attenuating Beclin1-mediated autophagy in the MG63 human osteosarcoma cell line

Authors:
- Hao Tao
- Feng Chen
- Haifei Liu
- Yanling Hu
- Yingzhen Wang
- Haiyan Li
View Affiliations

Affiliations: Department of Trauma Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China, Department of Joint Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China
Published online on: June 21, 2017 https://doi.org/10.3892/mmr.2017.6828
Pages: 1701-1706
Copyright: © Tao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anaberrant Wnt/β-catenin signaling pathway is frequently implicated in tumorigenesis. However, whether the Wnt/β‑catenin pathway plays a role in resistance to antitumor chemotherapy drugs remains unknown. In the present study, the process of autophagy was assessed following overexpression of the autophagy‑associated gene Beclin 1 in gemcitabine‑induced MG63 human osteosarcoma cells. Autophagy‑associated gene expression was measured following activation or inhibition of the Wnt/β‑catenin pathway in gemcitabine‑induced MG63 cells using reverse transcription‑quantitative polymerase chain reaction. In addition, the percentage of MG63 cell apoptosis was measured by flow cytometry following Wnt/β‑catenin pathway activation or inhibition. The results demonstrated that Beclin 1 overexpression induced autophagy and reduced gemcitabine‑induced apoptosis in MG63 human cell line. Furthermore, activation of the Wnt/β‑catenin signaling pathway attenuated autophagy and enhanced gemcitabine‑induced apoptosis. Additionally, the expression of Beclin 1 was reduced following Wnt/β‑catenin signaling pathway activation. The present study demonstrated that activation of the Wnt/β‑catenin signaling pathway may rescue chemotherapy drug resistance by downregulating the expression of Beclin 1.

View Figures

View References

1	Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R and Gandhi V: Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 22 4 Suppl 11:S3–S10. 1995.
2	Ahn DH, Krishna K, Blazer M, Reardon J, Wei L, Wu C, Ciombor KK, Noonan AM, Mikhail S and Bekaii-Saab T: A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: A retrospective analysis. Ther Adv Med Oncol. 9:75–82. 2017. View Article : Google Scholar : PubMed/NCBI
3	Hu Y, Fu JT, Shi D, Feng B and Shi Z: Clinical efficacy and safety of gemcitabine plus nedaplatin in the treatment of advanced nasopharyngeal carcinoma. J Cancer Res Ther. 12:C252–C255. 2016. View Article : Google Scholar : PubMed/NCBI
4	Khan MF, Gottesman S, Boyella R and Juneman E: Gemcitabine-induced cardiomyopathy: A case report and review of the literature. J Med Case Rep. 8:2202014. View Article : Google Scholar : PubMed/NCBI
5	Zhao S, Guo J, Sun L, Lv J and Qiu W: Gemcitabine-based chemotherapy in colon squamous cell carcinoma: A case report and literature review. Mol Clin Oncol. 6:561–565. 2017.PubMed/NCBI
6	Lee HS, Park SB, Kim SA, Kwon SK, Cha H, Lee DY, Ro S, Cho JM and Song SY: A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance. Sci Rep. 7:416152017. View Article : Google Scholar : PubMed/NCBI
7	Wei MY, Zhuang YF and Wang WM: Gemcitabine for the treatment of patients with osteosarcoma. Asian Pac J Cancer Prev. 15:7159–7162. 2014. View Article : Google Scholar : PubMed/NCBI
8	Mizushima N and Komatsu M: Autophagy: Renovation of cells and tissues. Cell. 147:728–741. 2011. View Article : Google Scholar : PubMed/NCBI
9	Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-Thompson ZW, Jimenez-Sanchez M, Korolchuk VI, Lichtenberg M, Luo S, et al: Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev. 90:1383–1435. 2010. View Article : Google Scholar : PubMed/NCBI
10	Choi AM, Ryter SW and Levine B: Autophagy in human health and disease. N Engl J Med. 368:1845–1846. 2013. View Article : Google Scholar : PubMed/NCBI
11	Kim J, Kundu M, Viollet B and Guan KL: AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 13:132–141. 2011. View Article : Google Scholar : PubMed/NCBI
12	Kang R, Zeh HJ, Lotze MT and Tang D: The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 18:571–580. 2011. View Article : Google Scholar : PubMed/NCBI
13	Muzes G and Sipos F: Anti-tumor immunity, autophagy and chemotherapy. World J Gastroenterol. 18:6537–6540. 2012. View Article : Google Scholar : PubMed/NCBI
14	Zhong JT, Xu Y, Yi HW, Su J, Yu HM, Xiang XY, Li XN, Zhang ZC and Sun LK: The BH3 mimetic S1 induces autophagy through ER stress and disruption of Bcl-2/Beclin 1 interaction in human glioma U251 cells. Cancer Lett. 323:180–187. 2012. View Article : Google Scholar : PubMed/NCBI
15	Polakis P: Wnt signaling and cancer. Genes Dev. 14:1837–1851. 2000.PubMed/NCBI
16	Logan CY and Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 20:781–810. 2004. View Article : Google Scholar : PubMed/NCBI
17	Petherick KJ, Williams AC, Lane JD, Ordonez-Moran P, Huelsken J, Collard TJ, Smartt HJ, Batson J, Malik K, Paraskeva C and Greenhough A: Autolysosomal β-catenin degradation regulates Wnt-autophagy-p62 crosstalk. Embo J. 32:1903–1916. 2013. View Article : Google Scholar : PubMed/NCBI
18	Sheen JH, Zoncu R, Kim D and Sabatini DM: Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. Cancer Cell. 19:613–628. 2011. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Sun T, Li X, Zhang P, Chen WD, Zhang HL, Li DD, Deng R, Qian XJ, Jiao L, Ji J, et al: Acetylation of Beclin 1 inhibits autophagosome maturation and promotes tumour growth. Nat Commun. 6:72152015. View Article : Google Scholar : PubMed/NCBI
21	Kim G, Kim JY, An HJ, Kang H, Kim TH, Shim JY, Heo JH, Park HL and Choi YK: The loss of E-cadherin is associated with the Epigenetic Alteration of CDH1 in breast cancer and it is also associated with an Abnormal beta-catenin expression in lobular carcinoma. Korean J Pathol. 43:400–407. 2009. View Article : Google Scholar
22	Luo S and Rubinsztein DC: Apoptosis blocks Beclin 1-dependent autophagosome synthesis: An effect rescued by Bcl-xL. Cell Death Differ. 17:268–277. 2010. View Article : Google Scholar : PubMed/NCBI
23	Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H and Levine B: Induction of autophagy and inhibition of tumorigenesis by Beclin 1. Nature. 402:672–676. 1999. View Article : Google Scholar : PubMed/NCBI
24	Boya P, Gonzaléz-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N, Métivier D, Meley D, Souquere S, Yoshimori T, et al: Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol. 25:1025–1040. 2005. View Article : Google Scholar : PubMed/NCBI
25	Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, et al: Promotion of tumorigenesis by heterozygous disruption of the Beclin 1 autophagy gene. J Clin Invest. 112:1809–1820. 2003. View Article : Google Scholar : PubMed/NCBI
26	Yorimitsu T and Klionsky DJ: Eating the endoplasmic reticulum: Quality control by autophagy. Trends Cell Biol. 17:279–285. 2007. View Article : Google Scholar : PubMed/NCBI
27	Aita VM, Liang XH, Murty VV, Pincus DL, Yu W, Cayanis E, Kalachikov S, Gilliam TC and Levine B: Cloning and genomic organization of Beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics. 59:59–65. 1999. View Article : Google Scholar : PubMed/NCBI
28	Garrington GE, Scofield HH, Cornyn J and Hooker SP: Osteosarcoma of the jaws. Analysis of 56 cases. Cancer. 20:377–391. 1967. View Article : Google Scholar : PubMed/NCBI
29	Chou AJ, Geller DS and Gorlick R: Therapy for osteosarcoma: Where do we go from here? Paediatr Drugs. 10:315–327. 2008. View Article : Google Scholar : PubMed/NCBI
30	Liang C, Li H, Shen C, Lai J, Shi Z, Liu B and Tao HM: Genistein potentiates the anti-cancer effects of gemcitabine in human osteosarcoma via the downregulation of Akt and nuclear factor-κB pathway. Anticancer Agents Med Chem. 12:554–563. 2012. View Article : Google Scholar : PubMed/NCBI
31	Mukubou H, Tsujimura T, Sasaki R and Ku Y: The role of autophagy in the treatment of pancreatic cancer with gemcitabine and ionizing radiation. Int J Oncol. 37:821–828. 2010.PubMed/NCBI
32	Teiten MH, Gaascht F, Cronauer M, Henry E, Dicato M and Diederich M: Anti-proliferative potential of curcumin in androgen-dependent prostate cancer cells occurs through modulation of the Wingless signaling pathway. Int J Oncol. 38:603–611. 2011.PubMed/NCBI
33	Hope C, Planutis K, Planutiene M, Moyer MP, Johal KS, Woo J, Santoso C, Hanson JA and Holcombe RF: Low concentrations of resveratrol inhibit Wnt signal throughput in colon-derived cells: Implications for colon cancer prevention. Mol Nutr Food Res. 52 Suppl 1:S52–S61. 2008.PubMed/NCBI